Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-09-11

Clinical Trial Update: Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) [Phase 2]

View source ↗

Summary

Phase II trial updating nilotinib use in newly diagnosed chronic phase chronic myeloid leukemia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Nilotinib (nilotinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia, Myelogenous, Chronic | Phase 2 | Status: COMPLETED | Results posted: 2019-09-11